FL-USARAD-HOLDINGS
USARAD Holdings Inc, a leading US Joint Commission Accredited teleradiology and telemedicine solutions provider recently launched SecondOpinions.com which offers a state of the art, proprietary, web-based consumer platform connecting patients globally to top U.S. physicians in any specialty and sub-specialty announced today that it will add a new feature to their services, Second Opinions Express TM .
Second Opinions Express™ is a new and unique offering which enables patients to ask a non-complicated general medical question and receive a quick and concise written response from a medical expert panel within as little as 30 minutes, 24/7/365. The service is affordable to all consumers at $19.95.
“We are excited to offer our new quick and affordable service to people across the globe,” said Michael Yuz, MD, MBA, CEO and Founder of SecondOpinions.com. “Statistics have shown that more than 70% of internet users search the web for health and medical information. Second Opinions ExpressTM has been developed, in part, to assist people interested in obtaining general medical information online but are not certain that the information they find is reliable. Our panel of medical experts ensures that patients receive credible, comprehensive and up-to-date medical information without spending a fortune.”
Second Opinions Express™ is not intended for diagnosis or treatment but will provide a general analysis and thoughts to be considered as a patient, doctor or caregiver moves forward.
SecondOpinions.com connects patients globally to top U.S. physicians in any specialty and sub-specialties. Within hours, patients receive a second opinion from a board certified physician. Patients simply upload their DVD images (MRI, CT etc) to a HIPAA regulated, secure, confidential platform and receive a report in the privacy of their own home or office. Obtaining a second opinion decreases medical errors, saves lives, and keeps healthcare costs down by preventing unnecessary surgeries and procedures. It gives patients the peace of mind they need and deserve. Quality assurance techniques such as second opinions will soon be mandated under The Patient Protection and the Affordable Care Act , also known as Obamacare.
Click this link to view our television interview that recently aired on WPLG-TV, ABC in Miami, Florida.
https://secondopinions.com/mediaroom/television-interviews.html
The prices for our standard radiology second opinions range from $29.00 -$99.00 per report. No appointments are needed, patients don’t have to wait days or weeks for a new consultation and the second opinion is received within hours of submission. Expert subspecialist radiologists are available 24/7/365 in all 50 states and across the globe. In addition, specialist and sub-specialist physicians in all medical fields provide second opinion consultations via telephone and video chat for as low as $49 per 5-minute consultation. This cost is less than many insurance co-payments.
For more information, please visit https://secondopinions.com/our-services/second-opinions-express.html
About SecondOpinions.com
SecondOpinons.com, a division of USARAD Holdings Inc is a medical consultation and second opinions leader providing second opinion consultation services in all areas of medicine including radiology. Utilizing a unique, proprietary patent- pending, cloud technology, SecondOpinions.com makes it possible to receive an expert second opinion in the privacy of one’s home or office.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140123005366/en/
Contact:
SecondOpinions.com
Debbie Liebross, 954-436-3644
debbie@secondopinions.com
or
Amber
Statler-Matthews, 954-649-9840
amber@secondopinions.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum